In line with trial results, real-world data suggest GLP-1 receptor agonists have certain benefits in patients with moderate to severe chronic kidney disease (CKD).

The risks for disease progression and death were lower for patients with stage 3b or higher CKD receiving GLP-1 ... RA on kidney function in patients with moderate to advanced CKD, although ...

Coya Therapeutics expands its pipeline, advancing COYA 303 with a dual immunomodulatory mechanism for inflammatory ... glucagon-like-peptide-1 receptor agonist (GLP-1 RA) designed for subcutaneous ...

Even as real-world experiences indicate that microdosing or off-label use of GLP-1 drugs can offer benefits, physicians recommend caution around the dosage, timing, and mechanisms of action for now.

Over a median of 3.68 years, adults with type 2 diabetes who added a GLP-1 agent to their treatment ... were likely driven by two main mechanisms of action -- the first being a reduction in ...

New research suggests that Ozempic and similar weight loss medications have the potential to be as big a game changer in ...

Company reported positive Phase 2b QUALITY study topline results for enobosarm + semaglutide (Wegovy®) with study meeting prespecified primary ...

Discover the latest developments in potential ALS treatments with COYA-302 and COYA-303, set to impact the $1.33 billion ...